# Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

> **NCT00494299** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 458 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00494299
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-07
- **Final completion:** 2010-11
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2013-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494299, "Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00494299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*